Regeneron Pharmaceuticals (REGN) said it currently expects that financial results for the third quarter 2024 will include an acquired in-process research and development charge of approximately $56 million on a pre-tax basis. This acquired IPR&D charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the third quarter by approximately $0.43. Regeneron's results for the third quarter have not been finalized.
The company noted that the IPR&D charge relates to development milestone and up-front payments in connection with collaboration and licensing agreements.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.